Kiora Pharmaceuticals: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Kiora Pharmaceuticals (NASDAQ:KPRX) reported its Q3 earnings, missing estimated earnings by 154.29% with an EPS of $-0.89 versus an estimate of $-0.35. Revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.27, which was followed by a 0.8% drop in the share price the next day.
November 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kiora Pharmaceuticals' Q3 earnings missed estimates significantly, which could negatively impact the stock price in the short term.
Kiora Pharmaceuticals reported a significant miss on its Q3 earnings, which is likely to negatively impact investor sentiment and could lead to a drop in the stock price. This is further supported by the company's past performance, where a beat on EPS was followed by a 0.8% drop in the share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100